Gremlin, A Potential Urinary Biomarker of Anca-Associated Crescentic Glomerulonephritis.

Gremlin renal overexpression has been reported in diabetic nephropathy, pauci-immune crescentic glomerulonephritis and chronic allograft nephropathy and has been implicated in the pathophysiology of the progression of renal damage. However, it is unknown whether urinary Gremlin can be associated with renal functional status, renal biopsy findings and outcome. To examine these associations we studied 20 patients with ANCA+ renal vasculitis and very high urinary Gremlin (354 ± 76 ug/gCr), 86 patients with other glomerular diseases and moderately elevated urinary Gremlin (83 ± 14 ug/gCr) and 11 healthy controls (urinary Gremlin 11.3 ± 2.4 ug/gCr). Urinary Gremlin was significantly correlated with renal expression of Gremlin (r = 0.64, p = 0.013) observed in cellular glomerular crescents, tubular epithelial cells and interstitial inflammatory cells. Moreover, urinary Gremlin levels were correlated with the number of glomerular crescents (r = 0.53; p < 0.001), renal CD68 positive cells (r = 0.71; p < 0.005), tubulointerstitial fibrosis (r = 0.50; p < 0.05), and serum creatinine levels (r = 0.60; p < 0.001). Interestingly, Gremlin expression was colocalized with CD68, CD163 (monocyte/macrophage markers) and CCL18 positive cells. ROC curve analysis showed that the cutoff value of urinary Gremlin in glomerular diseases as 43 ug/gCr with 72% of sensitivity and 100% of specificity [AUC: 0.96 (CI 95% 0.92-0.99] (p < 0.001). For ANCA+ renal vasculitis the value of urinary Gremlin of 241 ug/gCr had 55% of sensitivity and 100% of specificity [AUC: 0.81 (CI 95% 0.68-0.94) (p < 0.001]. Based on these results we propose that urinary Gremlin represents a non-invasive biomarker in ANCA+ renal vasculitis, and suggest a role of Gremlin in the formation of crescents.

Impact of fixed implant supported prostheses in edentulous patients: protocol for a systematic review.

INTRODUCTION: Edentulism is a debilitating and irreversible condition described as the 'final marker of disease burden for oral health'. Therapy with dental implants is being used on a large scale to replace missing teeth and to rehabilitate edentulous patients with overdentures and implant supported fixed dentures as a method of solving the problem of instability and lack of retention associated with conventional removable prostheses. Fixed implant supported prostheses are an alternative for implant rehabilitation treatment that allow patients to have new fixed teeth. They can be indicated in partial or total edentulous patients, and they can replace single teeth, or teeth and supporting tissues (hybrid prosthesis). They overcome the limitations of conventional dentures, increasing stability and retention, providing functional and psychological advantages for the patients. METHODS AND ANALYSIS: We will electronically search for randomised controlled trials evaluating the effects of fixed implant supported prostheses in edentulous patients in the following databases: Pubmed/MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. We will also try to obtain literature screening references of included studies, searching for trial protocols in the WHO International Clinical Trials Registry Platform, reviewing International Team for Implantology conference proceedings and searching for non-published studies through Open Gray. Two researchers will independently undertake selection of studies, data extraction and assessment of the quality of the included studies. Data synthesis and subgroup analyses will be performed using special Review Manager software. Data will be combined in a meta-analysis using a random effects model. RESULTS: The results will be presented as risk ratios for dichotomous data, and as mean difference or standardised mean difference for continuous data. ETHICS AND DISSEMINATION: No ethics approval is considered necessary. The results of this study will be disseminated via peer reviewed publications and social networks. TRIAL REGISTRATION NUMBER: CRD42015022086.